Hematology and Oncology
About UsThe Division of Hematology and Oncology is focused on improving patients’ therapeutic options and quality of life while working to better prevent, diagnose and treat cancer and hematologic disorders.
Our division houses laboratory-based investigators focused on a broad array of topics, including chemoprevention, cell signal pathways, epigenetics, immune-modulation, and nanotechnology theranostics.”
– William J. Gradishar, MD
What We Do
Faculty: Meet the Team
View individual profiles of our faculty members and learn about their research and clinical specialties.
Assistant Professor of Medicine (Hematology and Oncology)
Dr. VanderWeele did his medical and research training at the University of Chicago, where he developed a research program characterizing the heterogeneity and evolution of the cancer genome. He moved to the National Cancer Institute in Bethesda, MD, where he continued to seek to improve the treatment of prostate cancer based on patients’ specific genetic changes. He returned to Chicago in 2018 to join the GU cancer team at Northwestern University, where he continues to translate discoveries made at the bench into improved therapies in the clinic.
Associate Professor of Medicine (Hematology and Oncology)
I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.
Associate Professor of Medicine (Hematology and Oncology)
Interested in stem cell/bone marrow transplantation for malignant and non-malignant disorders, and patient outcomes after these transplants. Interested in cancer health disparities specifically in hematologic disorders. Interested in global health with improvement in outcomes for hematologic and oncologic conditions in all regions.
Professor of Medicine (Hematology and Oncology)
I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with ...
Professor of Medicine (Hematology and Oncology)
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior ...
Professor of Weinberg College of Arts and Sciences, Medicine (Hematology and Oncology) and Microbiology-Immunology
Interferon, STAT
Professor of Medicine (Hematology and Oncology)
The overarching goal of my involvement in translational research is to improve the outcome of patients with lymphoma. With scientists in the US and abroad, we are currently investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. More specifically, our research focuses on the biology of reactive oxygen species signaling pathways in lymphoma. Active investigations include: 1) the biology of the lactone diterpenoids in lymphoma; 2) the development of all trans retinoic acid (ATRA) and curcumin loaded nanodisks as a drug delivery vehicle in mantle cell lympho...
Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology)
Our research program is aimed at understanding the genetic program that underlies the pathogenesis of Glioblastoma multiforme (GBM), the most prevalent and malignant form of brain cancer. Applying a combination of cell/molecular biology, oncogenomic and mouse engineering approaches, we are dedicated to systematically characterize novel gliomagenic oncogenes and tumor suppressors. We will functionally delineate and validate these pathways towards pharmaceutical opportunities using sophisticated cell culture and animal models.
Research Assistant Professor of Medicine (Hematology and Oncology)
Dr. Beauchamp's research has focused on developing drugs for non-traditional targets through inhibiting protein-protein interactions in order to affect cellular function and target cancer cells. Current work is investigating novel interactors with mTORC components in order to developing novel therapeutic strategies that target the mTOR pathways in myeloid leukemias.
Professor of Medicine (Hematology and Oncology) and Biochemistry and Molecular Genetics
chronic leukemias, multiple myeloma, non-hodgkin's lymphoma
Diversity and Inclusion
The department works toward an environment of inclusion and support through the Diversity and Cultural Affairs Council and through several dedicated events and initiatives.
Housestaff Research Portal
Physician-Scientist Training & Resources
We offer a wide range of resources, mentorship opportunities and formal training programs to help our residents and fellows excel as physician-scientists. Explore all of the resources and hear from housestaff who are making research a major part of their career development plans.
Giving
Support What We Do
We invite your philanthropic partnership in helping us achieve our research and teaching missions each day.
Contact Terri Dillon for more information on supporting the Division of Hematology-Oncology at 312-503-4837 or terri-dillon@northwestern.edu.